Citi raised the firm’s price target on DexCom (DXCM) to $102 from $82 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom’s Strategic Advancements and Market Opportunities Justify Buy Rating with $105 Price Objective
- Dexcom Promotes Jacob S. Leach to President and COO
- Dexcom Stockholders Approve Equity Plan Amendments
- DexCom price target raised to $93 from $90 at Barclays
- Dexcom’s Strong Market Position and Growth Potential Justify Buy Rating Despite Margin Challenges